Gainers
- Fresh Tracks Therapeutics FRTX stock increased by 72.2% to $3.03 during Tuesday's after-market session. At the close, Fresh Tracks Therapeutics's trading volume reached 1.4 million shares. This is 2069.4% of its average volume over the last 100 days. The market value of their outstanding shares is at $9.1 million.
- Rigel Pharmaceuticals RIGL stock moved upwards by 19.04% to $1.75. Today's trading volume for this security ended up closing at 1.4 million shares, which is 46.7 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $302.4 million. As per the press release, Q4 earnings came out today.
- Kazia Therapeutics KZIA stock rose 8.0% to $1.08. The company's market cap stands at $22.0 million.
- Xtant Medical Holdings XTNT shares rose 7.36% to $1.02. The company's market cap stands at $110.8 million. As per the news, the Q4 earnings report came out today.
- AIM ImmunoTech AIM stock increased by 6.31% to $0.54. The market value of their outstanding shares is at $26.0 million.
- PLx Pharma PLXP stock rose 5.0% to $0.19. The market value of their outstanding shares is at $5.5 million.
Losers
- Miromatrix Medical MIRO shares declined by 27.5% to $1.79 during Tuesday's after-market session. The company's market cap stands at $37.4 million.
- Intelligent Bio Solutions INBS shares declined by 23.67% to $4.58. The market value of their outstanding shares is at $4.1 million.
- Satsuma Pharmaceuticals STSA shares declined by 10.66% to $0.84. The market value of their outstanding shares is at $27.8 million.
- BiomX PHGE stock decreased by 8.87% to $0.36. The company's market cap stands at $12.9 million.
- Bionomics BNOX stock decreased by 8.55% to $3.96. The company's market cap stands at $32.3 million.
- Akili AKLI shares declined by 7.61% to $1.7. The company's market cap stands at $132.4 million. As per the news, the Q4 earnings report came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in